Blog

Porvair (LSE:PRV) has reported record results for the six months to 31 May 2026, with revenue rising to £106.2 million and adjusted operating profit reaching £13.8 million. Strong demand across its aerospace, nuclear, life sciences, aluminium and superalloys businesses more than offset softer trading in petrochemical and industrial markets. Adjusted operating margin improved to 13.0%, earnings per share increased and the company raised its interim dividend by 9%. Net cash declined to £7.1 million, reflecting higher capital investment and spending on acquisitions during the period.

The group continued to expand through acquisitions, completing the purchase of Germany’s Drache Umwelttechnik and, after the reporting period, acquiring Italian filtration specialist GV Filtri Industriali and UK laboratory services provider Carekem. These transactions strengthen Porvair’s capabilities, particularly within its Metal Melt Quality division. Management said the integration of Drache is progressing well and highlighted the resilience of the group’s decentralised operating model. The company maintained its full-year guidance, expressing confidence that its diversified end markets and acquisition strategy will continue to support long-term growth despite ongoing geopolitical uncertainty and uneven conditions across some industrial sectors.

Porvair’s investment outlook remains underpinned by healthy profitability and a conservatively leveraged balance sheet. However, softer revenue trends in certain markets and less consistent free cash flow generation temper the overall picture. Technical indicators remain broadly neutral, while valuation appears reasonable, with the shares trading on a price-to-earnings multiple of around 21.9 and offering a relatively modest dividend yield.

More about Porvair

Porvair plc is a specialist engineering company focused on filtration, laboratory and environmental technologies. The group designs and manufactures high-performance consumable filtration products for regulated and mission-critical applications through its Aerospace & Industrial, Laboratory and Metal Melt Quality divisions. Its products serve customers across industries including aerospace, nuclear, life sciences, aluminium and superalloys, benefiting from recurring demand in specialist global markets.

Xtract Resources (LSE:XTR) has outlined significant progress during 2025 as the company continued its transition from exploration into mine development and near-term production. A key milestone was the expansion of its antimony strategy in Morocco through its majority-owned subsidiary Wildstone, which acquired the historic Amghas and Ighoud mines. The company also secured a new mining licence at Amghas, advanced plans for an on-site gravity processing plant and a future flotation facility, and strengthened its ambition to become a meaningful supplier of antimony to global markets.

In Zambia, Xtract expanded its exposure to high-grade copper and silver by increasing its interest in the Silverking project to 35%. The project now has a sulphide processing plant ready to receive ore, with development plans covering both open-pit and underground mining. To concentrate investment on its highest-priority assets, the company exited the Western Foreland and Chilibwe projects while raising £2 million through an equity fundraising. Xtract ended the year with £2.29 million in cash, although higher administrative costs, project expenditure and impairments associated with relinquished licences contributed to a wider annual loss.

While operational progress has accelerated, Xtract’s investment outlook continues to be influenced by its financial performance. The company remains affected by volatile earnings, a sharp decline in revenue during 2024 and continued cash burn. However, technical indicators have improved, with the share price trading above key moving averages and momentum strengthening. Valuation remains difficult to assess due to ongoing losses, reflected in a negative price-to-earnings ratio and the absence of a dividend.

More about Xtract Resources

Xtract Resources is a mining and exploration company focused on the development of copper, silver, antimony and, increasingly, tungsten projects. Operating across Morocco and Zambia, the company is targeting high-grade mineral deposits while progressing from early-stage exploration towards mine development and production to benefit from favourable long-term demand for critical and industrial metals.

Solid State plc (LSE:SOLI) has reported strong full-year results, with revenue increasing 23.2% to £154.1 million and adjusted profit before tax climbing 72% to £8.6 million. Growth was driven primarily by sustained demand from defence and security customers, which accounted for around 47% of group revenue. All three operating divisions recorded year-on-year growth, while gross margin improved by 200 basis points to 33.5%. The company also reported stronger returns on equity and invested capital, increased its dividend by 10%, reduced net debt and maintained an order book of more than £100 million despite receiving no new orders from the NATO Support and Procurement Agency (NSPA) during the period.

The group continued to invest in expanding its capabilities, including the opening of a new Integrated Computer Systems facility and a collaboration between Custom Power and Volklec to develop UK sovereign energy solutions for the defence sector. Solid State also secured a major communications contract with the British Army under Project CAIN and reported growing opportunities linked to AI-powered data centres and rising demand from non-NATO defence customers. Management said investment across FY26 and FY27 will be phased to support future growth and indicated that current trading is tracking ahead of market expectations. The company also announced the appointment of Victor Chavez CBE as non-executive chairman to lead the next stage of its strategic development.

Solid State’s investment outlook is supported by a solid financial position, positive corporate developments and continued contract momentum. However, profitability and cash flow remain areas to monitor, while valuation appears demanding based on a relatively high price-to-earnings multiple. Technical indicators currently point to positive short-term momentum, although investors will be looking for sustained earnings growth to justify the company’s valuation.

More about Solid State

Solid State plc is a UK-based electronics company supplying value-added components, systems and power solutions to customers operating in defence, industrial and other mission-critical sectors. Through its Systems, Power and Components divisions, the group provides rugged computing platforms, advanced communications equipment, battery technologies and specialist electronic components for use in demanding environments across defence, aerospace, energy, medical and industrial markets.

Mindflair (LSE:MFAI) has reported a year of active portfolio management, combining asset realisations with new investments across the artificial intelligence sector. The company completed the sale of its holding in Getvisibility for approximately £2.6 million, generating a profit of around £620,000 on its direct investment and significantly improving liquidity relative to its £2.9 million market capitalisation. During the year, Mindflair also reduced its position in Catenai, realised proceeds from an NRDC incubator investment, increased its year-end cash balance to £610,000 and repaid its remaining loan notes, leaving the group debt free.

Despite the stronger balance sheet, net asset value declined by 12.8% to £9.4 million, or 1.80 pence per share, largely due to a reduction in the valuation of its indirect Napster investment held through SVV1, together with operating expenses. As a result, the company recorded a pre-tax loss of £1.66 million compared with a profit in the previous year. Mindflair nevertheless continued to expand its exposure to artificial intelligence by completing eight new investments through SVV2, adding further investments via SVV3, increasing its stake in SVV2 and receiving a €600,000 cash inflow from the partial disposal of CameraMatics. The company said these transactions reflect its strategy of recycling capital into higher-growth AI opportunities despite ongoing valuation volatility.

Sure Valley Ventures remains the cornerstone of Mindflair’s investment strategy, with holdings across the SVV funds valued at £8.4 million at the year end. The portfolio provides diversified exposure to businesses operating in artificial intelligence, cybersecurity, immersive communications and metaverse technologies. However, the write-down of Napster following the failure to complete a previously announced US$3 billion funding round demonstrates the valuation risks inherent in early-stage technology investing. Mindflair noted that several portfolio companies have since announced strategic initiatives, new product launches and major technology partnerships as they continue to develop their businesses.

The company’s investment outlook remains constrained by limited revenue visibility and weak cash flow generation, despite an improvement in reported profitability and the strength of its debt-free balance sheet. Technical indicators also remain weak, with the shares trading below key moving averages and a negative MACD signal. Although the shares appear inexpensive on a price-to-earnings basis, that valuation is tempered by concerns over the quality and sustainability of reported earnings.

More about Mindflair plc

Mindflair plc is an AIM-listed investment company focused on next-generation technology businesses, with a particular emphasis on artificial intelligence applications across established industries. The company invests both directly and through three Sure Valley Ventures funds, as well as holding an interest in Sure Ventures plc, providing diversified exposure to AI, cybersecurity, immersive technology and other emerging digital sectors.

AdvancedAdvT (LSE:ADVT) has reported a strong set of annual results, with revenue increasing 23% to £53.4 million and adjusted EBITDA rising 28% to £14.5 million. Growth was supported by high levels of recurring revenue, strong customer renewal rates and continued operational efficiencies across the group’s software portfolio. Although reported basic earnings per share were affected by fair value adjustments, the company finished the year with £96.2 million of cash, providing financial flexibility to fund further investment while supporting its ongoing share buyback programme.

During the year, AdvancedAdvT strengthened its digital transformation offering through the acquisitions of HFX, GOSS and the AI-powered resource optimisation intellectual property of MatchingCore. The additions expand the group’s capabilities across cloud software, workforce management and enterprise digital services for customers in regulated industries, the public sector and SMEs. Management continues to prioritise the integration of artificial intelligence and automation into core business platforms, positioning the company to benefit from growing demand for digital transformation while pursuing disciplined organic expansion and targeted acquisitions.

AdvancedAdvT’s investment outlook remains underpinned by healthy profitability, strong operating margins and a debt-free balance sheet. However, variability in revenue growth and cash flow generation continues to moderate the overall picture. Technical indicators have improved, although longer-term trend signals have yet to fully confirm the recent momentum. With the shares trading at around 21 times earnings and no dividend currently available, valuation appears reasonable, while the share buyback programme and continued investment in AI capabilities provide additional support for future growth.

More about AdvancedAdvT Ltd.

AdvancedAdvT Limited is an international software company providing business solutions, healthcare compliance and human capital management platforms for organisations operating in complex and regulated industries. The group develops AI-enabled, cloud-based software that combines data analytics, automation and business intelligence to support digital transformation and modernise mission-critical business workflows.

Nativo Resources (LSE:NTVO) has reported further progress at its Tesoro Gold Concession in Peru, where it has extracted around 46 tonnes of mineralised vein material and completed a geological programme comprising 186 samples. The results have confirmed structurally controlled, narrow-vein gold mineralisation with several distinct high-grade shoots. Based on these findings, the company is directing operations towards the highest-priority areas within the Tesoro and Tesoro 1 vein systems, with the objective of selectively mining higher-grade zones, improving resource continuity and reducing geological uncertainty.

The company has also advanced preparations for its La Patona Gold Ore Processing Plant, completing engineering designs, equipment schedules, procurement planning and detailed cost estimates. With these elements now in place, the project is effectively ready for construction once financing has been secured. The facility is planned to begin operations with processing capacity of around 70 tonnes per day, initially focusing on high-grade ore. Confirmed third-party ore supply is expected to complement material from Nativo’s own mining operations, with commissioning targeted for late 2026. The project is intended to create an integrated mining and processing business while strengthening the company’s presence in Peru’s artisanal and small-scale gold mining sector.

Despite operational progress, Nativo’s investment outlook remains constrained by its financial position. The company continues to generate no revenue, reports ongoing losses, has negative shareholder equity and remains cash flow negative. Technical indicators are broadly neutral, with the shares trading below key longer-term moving averages, while valuation metrics offer limited support given the company’s negative earnings and lack of a dividend.

More about Nativo Resources Plc

Nativo Resources Plc is a London-listed precious metals company focused on gold exploration, mining and processing in Peru. Its principal assets include the Tesoro Gold Concession in southern Peru and the planned La Patona Gold Ore Processing Plant, which is designed to operate as a regional processing hub for ore sourced from both the company’s own projects and third-party miners.

Genedrive (LSE:GDR) has entered into a collaboration agreement with Thermo Fisher Scientific to develop the Genedrive CYP2C19 HT Kit, a high-throughput pharmacogenetic in vitro diagnostic test designed for use on Thermo Fisher’s QuantStudio 5 Dx PCR platform. The new assay is aimed at centralised laboratory testing and complements the company’s existing rapid CYP2C19 ID Kit for near-patient use. Genedrive is targeting UKCA certification by the end of 2026, with the initial commercial focus on NHS genomic laboratories across the UK.

The CYP2C19 HT Kit has been designed to support high-volume laboratory workflows through a multiplex PCR assay that operates directly from blood samples without the need for nucleic acid extraction. The test also features a broad allele panel to improve ethnic inclusivity and is supplied in a lyophilised format to simplify laboratory processes while reducing consumable requirements. By expanding its CYP2C19 product range into the central laboratory market, Genedrive aims to capitalise on growing clinical demand driven by recommendations from NICE and the American Heart Association for CYP2C19 genotyping in stroke and cardiovascular care. The collaboration also provides access to Thermo Fisher’s extensive installed base of diagnostic platforms, opening the door to a broader addressable market.

Despite the strategic opportunity, Genedrive’s investment outlook remains constrained by its financial position. The company continues to report significant losses, ongoing cash burn and a declining equity base, although it maintains relatively low debt levels. Technical indicators provide some support, with the shares trading above key moving averages and momentum remaining broadly neutral. However, valuation remains difficult to assess due to negative earnings and the absence of a dividend yield.

More about Genedrive

Genedrive plc is a UK-based commercial-stage diagnostics company specialising in rapid pharmacogenetic testing that supports safer and more effective prescribing in emergency and acute care settings. Its proprietary platform powers two CE-IVD-approved and NICE-recommended diagnostic tests already used within the NHS: the Genedrive CYP2C19 ID Kit, which identifies stroke patients less likely to respond to clopidogrel, and the MT-RNR1 ID Kit, designed to prevent antibiotic-induced hearing loss in newborns. The company is focused on expanding the adoption of precision diagnostics across routine clinical practice in the UK and international markets.